GURU.Markets stock price, segment price, and overall market index valuation
The company's share price PharmaCyte Biotech
PharmaCyte Biotech develops cell therapies for cancer and diabetes. Its stock price represents a venture bet on its unique "Cell-in-a-Box" technology. The price chart reflects a long history of clinical trials and a high degree of speculative value.
Share prices of companies in the market segment - Cancer stomach
PharmaCyte Biotech is developing "Cell-in-a-Box," a cell therapy that encapsulates living cells to deliver drugs directly to tumors, such as those of the pancreas. We've categorized it under "Stomach Cancer." The chart below shows the dynamics of this breakthrough biotech sector.
Broad Market Index - GURU.Markets
PharmaCyte Biotech is a biotech company developing cell therapies for pancreatic cancer and diabetes. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
PMCB - Daily change in the company's share price PharmaCyte Biotech
PharmaCyte Biotech, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its cell therapy for cancer.
Daily change in the price of a set of shares in a market segment - Cancer stomach
PharmaCyte Biotech develops cell therapies for cancer, particularly pancreatic cancer. This is a cutting-edge and highly risky segment of biotech. The chart below illustrates the high volatility typical of oncology developments, providing context for PMCB stock valuation.
Daily change in the price of a broad market stock, index - GURU.Markets
PharmaCyte is a biotech company developing cell therapy for pancreatic cancer. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization PharmaCyte Biotech
For PharmaCyte Biotech, the year's performance is a story about the development of its unique cell therapy for pancreatic cancer. Its market capitalization over the next 12 months depends entirely on FDA approvals and progress in clinical trials. The success of its "Cell-in-a-Box®" technology could offer a new approach to treating one of the most deadly cancers.
Annual dynamics of market capitalization of the market segment - Cancer stomach
PharmaCyte, as an early-stage biotech, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cell therapy for cancer. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
PharmaCyte Biotech is developing innovative cell therapies for pancreatic cancer and diabetes. Its year-over-year market capitalization is a classic example of an early-stage biotech company, where investors bet on breakthrough science and the stock price is driven by news of clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization PharmaCyte Biotech
PharmaCyte is a biotech company developing cell-based cancer therapies. Its monthly performance is entirely dependent on its interactions with the FDA and progress toward the start of key clinical trials. Regulatory news is the primary driver.
Monthly dynamics of market capitalization of the market segment - Cancer stomach
PharmaCyte Biotech is developing cell therapy for pancreatic cancer and diabetes. Its "Cell-in-a-Box" technology encapsulates living cells for drug delivery. Success depends on clinical data. The oncology sector's growth reflects the overall interest in cell therapy, providing a backdrop for evaluating this unique platform.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
PharmaCyte Biotech is developing cell therapy for pancreatic cancer, one of the most deadly forms of cancer. The company's shares are driven solely by news of clinical trials. Their performance is completely disconnected from market cycles and reflects investor hopes for a breakthrough in the treatment of this devastating disease.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization PharmaCyte Biotech
PharmaCyte Biotech is developing a cell therapy for pancreatic cancer using a unique cell encapsulation technology. Its stock has been on a roller coaster this week, driven by news of clinical trials that are threatening the future of this innovative platform.
Weekly dynamics of market capitalization of the market segment - Cancer stomach
PharmaCyte Biotech is developing cell therapies for pancreatic cancer and diabetes. This is a cutting-edge, but highly risky, field. The company's stock price is entirely driven by news of clinical trials. The chart will reveal how unique its path is in the biotech sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
PharmaCyte Biotech develops cell therapy for cancer. Its shares are caught in a world of hope and disappointment in clinical trials. The chart clearly shows how its performance is completely disconnected from general market trends and driven solely by scientific developments.
Market capitalization of the company, segment and market as a whole
PMCB - Market capitalization of the company PharmaCyte Biotech
PharmaCyte Biotech's market capitalization reflects investors' valuation of its unique "Cell-in-a-Box" cell therapy technology. The chart illustrates the market's belief that encapsulated cells will deliver drugs directly to pancreatic tumors. Its high volatility reflects the long and risky path of this innovative technology.
PMCB - Share of the company's market capitalization PharmaCyte Biotech within the market segment - Cancer stomach
PharmaCyte Biotech is developing a unique "Cell-in-a-Box" cell therapy technology for the treatment of cancer and diabetes. Its market share is negligible, but it is based on a breakthrough idea. Its capitalization is a bet on its platform, which encapsulates living cells to deliver drugs directly to their target.
Market capitalization of the market segment - Cancer stomach
Below is a chart showing the overall value of the entire oncology sector. For PharmaCyte Biotech, with its unique "cell encapsulation" technology for cancer treatment, this line represents a map of the future. The rising chart reflects investors' belief that new drug delivery platforms will make therapy more precise and effective.
Market capitalization of all companies included in a broad market index - GURU.Markets
PharmaCyte Biotech is developing cell therapy for pancreatic cancer. Its market capitalization is based on its unique "living cell" technology. In the overall market, this represents a significant portion of the hope for a breakthrough in the fight against one of the most deadly cancers.
Book value capitalization of the company, segment and market as a whole
PMCB - Book value capitalization of the company PharmaCyte Biotech
PharmaCyte Biotech develops cell therapies for cancer. Its book value is derived from its financial resources and its unique Cell-in-a-Box cell encapsulation technology. This is its capital for advancing innovative treatments through clinical trials. How has this value changed? The chart below shows.
PMCB - Share of the company's book capitalization PharmaCyte Biotech within the market segment - Cancer stomach
PharmaCyte Biotech develops cell therapy for cancer treatment. Its unique "Cell-in-a-Box" technology requires sophisticated infrastructure, including in-house GMP-compliant facilities for encapsulating living cells. The chart shows the company's share of the physical infrastructure required for this cutting-edge biotechnology initiative.
Market segment balance sheet capitalization - Cancer stomach
PharmaCyte is a biotechnology company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. PharmaCyte focuses on developing cell therapies, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
PharmaCyte Biotech's assets are not drugs, but rather a unique "Cell-in-a-Box" technology for encapsulating living cells, which are then implanted for targeted drug delivery, specifically for the treatment of pancreatic cancer. These assets reflect the potential of this cell therapy platform.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - PharmaCyte Biotech
PharmaCyte Biotech develops cell therapies for cancer and diabetes. Its market value is derived from its unique "Cell-in-a-Box" cell encapsulation technology. Investors are betting on this platform rather than their current assets.
Market to book capitalization ratio in a market segment - Cancer stomach
PharmaCyte Biotech is developing cell therapy for cancer treatment. It's an early-stage technology. Its high valuation on this chart reflects investors' pure faith in its scientific approach, despite the enormous risks and long road to commercialization.
Market to book capitalization ratio for the market as a whole
PharmaCyte Biotech is developing cell therapy for cancer. Its cell encapsulation technology could be a breakthrough. The company's market capitalization reflects investors' faith in its unique scientific approach. This chart shows how much the market is willing to pay for potentially revolutionary, yet unproven, medical platforms.
Debts of the company, segment and market as a whole
PMCB - Company debts PharmaCyte Biotech
PharmaCyte, a biotech company developing cell therapies for cancer, is in the clinical stage and relies entirely on external funding for its research. This graph illustrates the enormous financial demands and high risk associated with attempting to commercialize a breakthrough but complex medical technology.
Market segment debts - Cancer stomach
PharmaCyte Biotech is developing cell therapies for cancer, specifically pancreatic cancer, using a unique cell encapsulation technology. This chart illustrates how the clinical-stage company is funding the development of its complex and innovative, yet risky, platform, a long and capital-intensive process.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio PharmaCyte Biotech
PharmaCyte Biotech develops cell therapies for cancer, particularly pancreatic cancer. Live cell encapsulation is a cutting-edge but very expensive technology. This chart illustrates the company's reliance on debt to fund its innovative, yet high-risk and time-consuming, clinical trials.
Market segment debt to market segment book capitalization - Cancer stomach
PharmaCyte Biotech develops cell therapies for cancer, particularly pancreatic cancer, one of the most deadly forms of cancer. This chart shows how the company finances its cutting-edge, yet highly risky, research. It relates its debt structure to the broader biotech landscape.
Debt to book value of all companies in the market
PharmaCyte Biotech develops cell therapies for cancer, particularly pancreatic cancer. This is one of the most advanced and capital-intensive areas of biotech. How heavily will the company rely on debt financing? This chart of total debt in the economy helps assess the scale of future financial risks.
P/E of the company, segment and market as a whole
P/E - PharmaCyte Biotech
PharmaCyte Biotech develops cell therapies for pancreatic cancer and other solid tumors. This chart shows how investors value its unique "Cell-in-a-Box" technology. The valuation is highly speculative and depends on the results of clinical trials.
P/E of the market segment - Cancer stomach
PharmaCyte Biotech is developing cell therapies for cancer and diabetes using its "Cell-in-a-Box" technology, which encapsulates living cells for drug delivery. This chart illustrates the average valuation in the cell therapy sector, where investors are betting on breakthrough but high-risk biotech platforms.
P/E of the market as a whole
PharmaCyte Biotech is a biotech company developing cell therapies for cancer and diabetes based on its proprietary cellulose encapsulation technology (Cell-in-a-Box). This chart reflects investors' overall risk appetite. It helps understand whether PMCB's high valuation is based on faith in its unique platform or is moving in line with overall biotech sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company PharmaCyte Biotech
PharmaCyte Biotech is developing cell therapy technology for the treatment of pancreatic cancer and diabetes. Their approach involves encapsulating living cells for drug delivery. This chart illustrates the investor confidence in this innovative platform and its potential to treat difficult-to-treat diseases, which informs the company's valuation.
%20P%2FE%20PharmaCyte%20Biotech&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-PharmaCyte-Biotech&v=1772563977996 "Chart of the company's future (projected) P/E PharmaCyte Biotech")
Future (projected) P/E of the market segment - Cancer stomach
PharmaCyte Biotech is developing cell therapy for pancreatic cancer and diabetes. Its "Cell-in-a-Box" technology encapsulates living cells. The chart shows the sector's expected future profits, helping to understand how high investor expectations are for this innovative, yet risky, platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20stomach&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-stomach&v=1772563978034 "Future (projected) P/E graph of the market segment - Cancer stomach")
Future (projected) P/E of the market as a whole
PharmaCyte Biotech is developing cell therapy for pancreatic cancer and diabetes. The technology is based on the encapsulation of living cells. This biotech risk appetite chart reflects investors' willingness to fund cutting-edge and highly complex treatments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772563978058 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit PharmaCyte Biotech
PharmaCyte Biotech is developing cell therapy for cancer, particularly pancreatic cancer. The technology involves encapsulating living cells that activate chemotherapy directly within the tumor. This chart shows the investment in this cutting-edge and complex treatment method, which is currently in clinical trials.
Profit of companies in the market segment - Cancer stomach
PharmaCyte Biotech develops cell therapy for cancer treatment by encapsulating living cells that activate chemotherapy drugs directly within tumors. This innovative approach is a key driver of the company's growth. This chart shows the overall profitability of the gastric cancer and other oncology treatment sectors, where cell therapy is opening up new horizons.
Overall market profit
PharmaCyte Biotech is developing cell therapy for the treatment of oncological diseases, particularly pancreatic cancer. The company is in clinical trials. Its future depends entirely on the success of these studies. The overall economic situation, as shown in this chart, does not affect the need for innovative cancer treatments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company PharmaCyte Biotech
PharmaCyte Biotech is developing a cell therapy for cancer treatment by encapsulating living cells that activate chemotherapy drugs directly within the tumor. Future profits depend on the success of this complex technology. This chart reflects analysts' speculative expectations for the future of this innovative approach.
%20profit%20of%20the%20company%20PharmaCyte%20Biotech&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-PharmaCyte-Biotech&v=1772563978202 "Graph of future (projected) profit of the company PharmaCyte Biotech")
Future (predicted) profit of companies in the market segment - Cancer stomach
PharmaCyte Biotech develops cell therapies for cancer and diabetes. Its "Cell-in-a-Box" technology encapsulates living cells to deliver drugs directly to tumors. This chart shows revenue projections for the gastric cancer treatment sector, providing context for evaluating PharmaCyte's innovative approach to targeted therapy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20stomach&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-stomach&v=1772563978230 "Graph of future (predicted) profits of companies in a market segment - Cancer stomach")
Future (predicted) profit of the market as a whole
PharmaCyte Biotech is developing cell therapies for cancer and diabetes. It's an early-stage company, entirely dependent on funding for clinical trials. This earnings guidance chart reflects overall investor sentiment and their willingness to invest in high-risk but potentially breakthrough medical technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772563978247 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - PharmaCyte Biotech
PharmaCyte Biotech is developing cell therapies for the treatment of cancer and diabetes. Being in the preclinical stage, the company has no revenue. This chart reflects investors' faith in its unique "Cell-in-a-Box" technology and its long-term potential.
P/S market segment - Cancer stomach
PharmaCyte Biotech is developing innovative cell therapies for pancreatic cancer and diabetes. Their Cell-in-a-Box technology encapsulates living cells that can produce drugs directly at the site of disease. This chart reflects the average revenue estimate for the sector, helping to gauge expectations for this cutting-edge biotech platform.
P/S of the market as a whole
PharmaCyte Biotech is developing cell therapy for cancer, particularly pancreatic cancer, by encapsulating living cells to deliver drugs directly to the tumor. This graph highlights that the evaluation of such breakthrough, yet risky, technologies is based solely on the belief in future clinical success.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company PharmaCyte Biotech
PharmaCyte Biotech develops cell therapy for pancreatic cancer and other solid tumors. Its technology encapsulates cells that activate chemotherapy directly within the tumor. Its revenue valuation is crucial, reflecting investors' confidence in the potential of this unique platform to improve cancer treatment outcomes.
%20P%2FS%20PharmaCyte%20Biotech&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-PharmaCyte-Biotech&v=1772563978474 "The graph of the company's future (projected) P/S PharmaCyte Biotech")
Future (projected) P/S of the market segment - Cancer stomach
PharmaCyte Biotech is developing cell therapies for cancer and diabetes based on its Cell-in-a-Box technology, which encapsulates living cells. This chart reflects how investors view the company's future revenues relative to the biotech sector. It demonstrates the market's confidence in the potential of this unique platform for developing new treatments.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20stomach&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-stomach&v=1772563978530 "Future (projected) P/S market segment graph - Cancer stomach")
Future (projected) P/S of the market as a whole
PharmaCyte Biotech is developing a cell therapy for pancreatic cancer by encapsulating living cells that activate chemotherapy directly within the tumor. The company's future depends on the success of this complex technology. This market forecast chart reflects investor confidence in breakthrough and innovative approaches to cancer treatment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772563978587 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales PharmaCyte Biotech
This metric for PharmaCyte Biotech reflects the financial activity of the company, which is developing cell therapies for the treatment of pancreatic cancer and diabetes. Being in clinical trials, the company has no commercial revenue, and its cash flows are related to research and development expenses.
Sales of companies in the market segment - Cancer stomach
PharmaCyte Biotech is developing cell therapies for the treatment of cancer and diabetes. Its unique Cell-in-a-Box technology encapsulates living cells to deliver drugs directly to tumors. While the company is in the clinical stage, it has no revenue yet, but its future potential depends on the success of this innovative platform.
Overall market sales
PharmaCyte Biotech develops cell therapies for cancer and diabetes using a unique cell encapsulation technology. The company is at the forefront of biotechnology. This general economics chart does not reflect PharmaCyte's prospects, which are determined solely by scientific breakthroughs and clinical trial results.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company PharmaCyte Biotech
PharmaCyte Biotech is developing cell therapies for cancer and diabetes based on its "Cell-in-a-Box" technology, which encapsulates living cells for drug delivery. Future revenues are dependent on the success of clinical trials. This chart reflects analyst expectations for the commercial potential of this unique therapeutic delivery platform.
%20sales%20of%20the%20company%20PharmaCyte%20Biotech&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-PharmaCyte-Biotech&v=1772563978789 "Schedule of future (projected) sales of the company PharmaCyte Biotech")
Future (projected) sales of companies in the market segment - Cancer stomach
PharmaCyte Biotech is developing cell therapies for pancreatic cancer and other solid tumors. This chart shows the outlook for the oncology sector. Will a breakthrough in the treatment of difficult-to-treat cancers spur growth across the entire market? This chart provides an overview of the overall scientific and commercial potential.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20stomach&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-stomach&v=1772563978836 "Schedule of future (projected) sales of companies in the market segment - Cancer stomach")
Future (projected) sales of the market as a whole
PharmaCyte Biotech is developing cell therapies for cancer and diabetes. It's an early-stage company, and its value depends on the scientific potential of its platform and preclinical data. The general economic cycles reflected in this chart bear no relation to the fundamental scientific processes that will determine the company's future.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772563978888 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality PharmaCyte Biotech
PharmaCyte Biotech is developing cell therapy for pancreatic cancer and other solid tumors. Its technology involves encapsulating cells that directly activate chemotherapy within the tumor. This graph illustrates its extensive research journey. Profitability is a distant goal, dependent on the success of this complex and innovative approach.
Market segment marginality - Cancer stomach
PharmaCyte Biotech, Inc. develops cell therapies for the treatment of cancer, particularly pancreatic cancer, based on its Cell-in-a-Box® technology. This chart depicts the company's financial position at the clinical stage, whose profitability depends on the success of its unique platform in treating difficult-to-treat cancers.
Market marginality as a whole
PharmaCyte Biotech develops cell therapy for pancreatic cancer. The company is at the forefront of the fight against one of the most deadly cancers. This total return chart reflects investor appetite for high-risk biotech projects that require multi-year funding to achieve results.
Employees in the company, segment and market as a whole
Number of employees in the company PharmaCyte Biotech
PharmaCyte Biotech develops cell therapies for pancreatic cancer and diabetes. Its unique "Cell-in-a-Box" technology requires a highly specialized team. This chart shows how the biotech startup manages its small team during clinical trials, where each step requires significant scientific and financial investment.
Share of the company's employees PharmaCyte Biotech within the market segment - Cancer stomach
PharmaCyte Biotech develops cell therapy technology for the treatment of cancer and diabetes, encapsulating living cells for drug delivery. This cutting-edge biotechnology requires a team of cell biologists and engineers. This chart shows the company's market share, reflecting its scientific potential and the stage of development of its unique therapeutic platform.
Number of employees in the market segment - Cancer stomach
PharmaCyte Biotech is developing cell therapy for pancreatic cancer and diabetes. Its Cell-in-a-Box technology encapsulates living cells that produce the drug directly in the body. The chart shows employment in the gastric oncology sector. This innovative approach has the potential to revolutionize drug delivery.
Number of employees in the market as a whole
PharmaCyte Biotech develops cell therapies for cancer and diabetes. This is cutting-edge biotechnology. The company's growth in staff is not a reflection of economics, but a direct consequence of research progress. Given the overall dynamics in this chart, PharmaCyte represents a venture capitalist sector, where jobs are being created aimed at revolutionizing medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company PharmaCyte Biotech (PMCB)
PharmaCyte Biotech develops a unique "Cell-in-a-Box" technology for cell therapy, primarily for the treatment of pancreatic cancer. They are cutting-edge biotech. This chart shows the high premium the market is placing on their platform. It reflects the market value per employee, which is the net value of their breakthrough IP.
%20of%20the%20company%20PharmaCyte%20Biotech%20(PMCB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-PharmaCyte-Biotech-PMCB&v=1772563979274 "Chart of market capitalization per employee (in thousands of dollars) of the company PharmaCyte Biotech (PMCB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer stomach
PharmaCyte Biotech (PMCB) is developing cell therapies for pancreatic cancer and diabetes. In this cutting-edge biotech field, this chart represents the valuation of its "Cell-in-a-Box" cell encapsulation technology. The very high market capitalization per employee suggests investors see potential in this platform for the safe and effective delivery of live cells into the body.
%20by%20market%20segment%20-%20Cancer%20stomach&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-stomach&v=1772563979276 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer stomach")
Market capitalization per employee (in thousands of dollars) for the overall market
PharmaCyte Biotech is developing cell therapy for pancreatic cancer. Its valuation is a bet on a scientific breakthrough in one of the most deadly forms of cancer. The chart shows a huge valuation per employee, as investors believe the company's unique technology can bring hope to patients with this devastating diagnosis.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772563979286 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company PharmaCyte Biotech (PMCB)
PharmaCyte Biotech is a biotech company developing cell therapy for cancer (specifically, pancreatic cancer) using its unique "Cell-in-a-Box" technology. This graph shows the company is in the R&D phase. The loss per employee reflects the investment in scientists to bring this complex technology to the clinic.
%20Chart%20PharmaCyte%20Biotech%20(PMCB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-PharmaCyte-Biotech-PMCB&v=1772563979344 "Company Profit Per Employee (in thousands of dollars) Chart PharmaCyte Biotech (PMCB)")
Profit per employee (in thousands of dollars) in the market segment - Cancer stomach
PharmaCyte Biotech, Inc. is developing cell therapies for cancer and diabetes using its "Cell-in-a-Box" technology. In advanced biotechnology, per-employee efficiency reflects the potential of their unique platform. This graph shows the financial return per team, allowing one to assess progress toward commercialization of this revolutionary treatment.
%20in%20the%20market%20segment%20-%20Cancer%20stomach&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-stomach&v=1772563979404 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer stomach")
Profit per employee (in thousands of dollars) for the market as a whole
PharmaCyte Biotech is a biotech company developing a "Cell-in-a-Box" cell therapy platform for the treatment of pancreatic cancer and diabetes. It's an R&D company. This chart, which shows average market profitability, demonstrates how the biotech model, with its small workforce and high stakes, differs from the rest of the economy.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772563979695 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee PharmaCyte Biotech (PMCB)
PharmaCyte Biotech is developing cell therapy for cancer treatment. Like many early-stage biotechs, there is no revenue per employee. The graph is important as a proxy for future potential: if their unique technology is successful, this figure could skyrocket, reflecting the enormous value of their scientific research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-PharmaCyte-Biotech-PMCB&v=1772563979759 "Sales chart per company employee PharmaCyte Biotech (PMCB)")
Sales per employee in the market segment - Cancer stomach
PharmaCyte Biotech is a clinical-stage biotech developing a unique "Cell-in-a-Box" platform (encapsulating living cells) for targeted chemotherapy delivery (for example, for pancreatic cancer). They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer for PMCB's R&D staffing efficiency.
Sales per employee for the market as a whole
PharmaCyte Biotech is developing a unique "Cell-in-a-Box" technology that encapsulates living cells for drug delivery, primarily for the treatment of pancreatic cancer. This chart reflects their R&D status: the company is in clinical trials and has no commercial revenue.
Short shares by company, segment and market as a whole
Shares shorted by company PharmaCyte Biotech (PMCB)
PharmaCyte (PMCB) is developing a cell therapy for pancreatic cancer, one of the most deadly forms of cancer. This chart shows the number of short positions. The short positions reflect the extremely low odds of success in this area and the company's long history without commercial products.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-PharmaCyte-Biotech-PMCB&v=1772563979830 "Short Shares Chart for the Company PharmaCyte Biotech (PMCB)")
Shares shorted by market segment - Cancer stomach
PharmaCyte Biotech (PMCB) is developing cell therapies for pancreatic cancer and diabetes using "Cell-in-a-Box" technology (cell encapsulation). This chart aggregates short positions across the entire oncology biotech sector. It reflects general investor skepticism about the risks of clinical trials.
Shares shorted by the overall market
PharmaCyte Biotech is developing a cell therapy for pancreatic cancer. This involves a long and complex R&D process. This chart illustrates the overall market pessimism. When investors panic, they're reluctant to fund biotechs. They see a cash burn and fear they'll run out of money before trials are completed.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator PharmaCyte Biotech (PMCB)
PharmaCyte Biotech is developing a unique cell therapy ("Cell-in-a-Box") for the treatment of cancer, particularly pancreatic cancer. This is an extremely challenging goal. This graph is a "cardiogram" of hope. It "overheats" to the extreme on news about the progress of their clinical trials and "cools" on information about delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-PharmaCyte-Biotech-PMCB&v=1772563980026 "RSI 14 indicator chart for the company's stock PharmaCyte Biotech (PMCB)")
RSI 14 Market Segment - Cancer stomach
PharmaCyte (PMCB) is a biotech company developing cell-based cancer therapy. Their idea is to implant capsules containing cells that "activate" chemotherapy directly into tumors. This chart measures overall sentiment in the oncology sector. It helps distinguish the success of PMCB's technology from the overall "overheating" or "overselling" of the biotech sector.
RSI 14 for the overall market
For PharmaCyte Biotech, a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PMCB (PharmaCyte Biotech)
PharmaCyte Biotech is developing "Cell-in-a-Box" technology: an implantable capsule that delivers live cells to treat pancreatic cancer and diabetes. This chart shows the highly speculative average price target from analysts, based on their belief in this breakthrough R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PMCB-PharmaCyte-Biotech&v=1772563980117 "A chart showing analyst consensus forecasts for the expected stock price. PMCB (PharmaCyte Biotech)")
The difference between the consensus estimate and the actual stock price PMCB (PharmaCyte Biotech)
PharmaCyte is a biotech company with a "Cell-in-a-Box" platform. Their technology "packages" living cells into capsules for targeted chemotherapy delivery (for pancreatic cancer). This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in this sophisticated R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PMCB-PharmaCyte-Biotech&v=1772563980202 "A chart showing the difference between the consensus forecast and the actual stock price. PMCB (PharmaCyte Biotech)")
Analyst consensus forecast for stock prices by market segment - Cancer stomach
PharmaCyte (PMCB) is a biotech company developing cell-in-a-box therapy, which encapsulates living cells to deliver drugs directly to tumors (pancreatic cancer). This chart shows overall expectations for the oncology sector, reflecting experts' confidence in this R&D platform.
Analysts' consensus forecast for the overall market share price
PharmaCyte Biotech is a biotech company developing cell-in-a-box therapies for pancreatic cancer and diabetes. This is a high-risk sector. This chart reflects the overall market "risk appetite." For PMCB, a clinical-stage company with an innovative platform, overall market optimism (risk appetite) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index PharmaCyte Biotech
PharmaCyte is a veteran R&D company that has rebooted itself. Their signature technology is Cell-in-a-Box: encapsulating living cells to deliver drugs (such as chemotherapy) directly to tumors (such as pancreatic cancer). This graph is a clear indicator of faith in their R&D. It reflects their (very long and risky) path to FDA approval and their race to keep up with the money.
AKIMA Market Segment Index - Cancer stomach
PharmaCyte Biotech (PMCB) uses Cell-in-a-Box technology. They package live cells (which produce chemotherapy) into capsules and implant them near the tumor (for example, pancreatic cancer). This allows them to attack the cancer locally without poisoning the entire body. This graph shows the average index for the segment, helping to assess how this technology compares.
The AKIM Index for the overall market
PharmaCyte Biotech is a biotech company using cell-in-a-box technology to treat cancer and diabetes. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific platform compares to overall economic trends.
